Andrew Hollman Meyer Janux Therapeutics, Inc. (JANX) insider trading activity

Andrew Hollman Meyer is Chief Business Officer of Janux Therapeutics, Inc.. Currently has a direct ownership of 83,095 shares of JANX, which is worth approximately $2.43 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 1,879 shares (Common Stock) at a price of $13.73 per share, resulting in proceeds of $25,798. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 83.1K

1.16% 3M change

1.16% 12M change

Total Value Held $2.43 Million

Andrew Hollman Meyer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	SELL Open market or private sale	$25,798 $13.73 p/Share	1,879 Reduced 2.21%	83,095 Common Stock
Dec 01 2025	SELL Open market or private sale	$110,588 $33.18 p/Share	3,333 Reduced 3.77%	84,974 Common Stock
Dec 01 2025	BUY Exercise of conversion of derivative security	$35,296 $10.59 p/Share	3,333 Added 3.64%	88,307 Common Stock
Nov 14 2025	SELL Open market or private sale	$99,990 $30.0 p/Share	3,333 Reduced 3.77%	84,974 Common Stock
Nov 14 2025	BUY Exercise of conversion of derivative security	$35,296 $10.59 p/Share	3,333 Added 3.64%	88,307 Common Stock
Oct 28 2025	SELL Open market or private sale	$500,949 $30.06 p/Share	16,665 Reduced 16.87%	82,139 Common Stock
Oct 28 2025	BUY Exercise of conversion of derivative security	$123,321 $7.4 p/Share	16,665 Added 14.43%	98,804 Common Stock

May 01 2025	SELL Open market or private sale	$107,589 $32.28 p/Share	3,333 Reduced 3.9%	82,139 Common Stock
May 01 2025	BUY Exercise of conversion of derivative security	$14,031 $4.21 p/Share	3,333 Added 3.75%	85,472 Common Stock
Apr 21 2025	SELL Open market or private sale	$100,020 $30.0 p/Share	3,334 Reduced 3.9%	82,139 Common Stock
Apr 21 2025	BUY Exercise of conversion of derivative security	$14,036 $4.21 p/Share	3,334 Added 3.75%	85,473 Common Stock
Mar 03 2025	SELL Open market or private sale	$107,888 $32.36 p/Share	3,334 Reduced 3.9%	82,139 Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	$14,036 $4.21 p/Share	3,334 Added 3.75%	85,473 Common Stock
Feb 03 2025	SELL Open market or private sale	$142,761 $42.82 p/Share	3,334 Reduced 3.9%	82,139 Common Stock
Feb 03 2025	BUY Exercise of conversion of derivative security	$14,036 $4.21 p/Share	3,334 Added 3.75%	85,473 Common Stock
Jan 02 2025	SELL Open market or private sale	$741,903 $55.64 p/Share	13,334 Reduced 13.97%	82,139 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	18,000 Added 15.86%	95,473 Common Stock
Dec 19 2024	BUY Exercise of conversion of derivative security	$169,261 $17.13 p/Share	9,881 Added 11.31%	77,473 Common Stock
Sep 27 2024	SELL Open market or private sale	$2,298,000 $45.96 p/Share	50,000 Reduced 42.52%	67,592 Common Stock
Sep 27 2024	BUY Exercise of conversion of derivative security	$210,500 $4.21 p/Share	50,000 Added 29.83%	117,592 Common Stock

AHM

Andrew Hollman Meyer

Chief Business Officer

La Jolla, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JANX shares.

Notify only if

Value

Insider Trading

Get notified when an Janux Therapeutics, Inc. insider buys or sells JANX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Janux Therapeutics, Inc.

Track Activities on JANX

Account